Editas Medicine Nabs Former Bristol-Myers Squibb Exec as New CSO
Published: Aug 22, 2016
“Charlie has an impressive track record of translating exciting science into real medicines for patients in need,” said
“As a leader in the field, Editas is building an impressive and diversified pipeline focused on treating patients with a broad range of genetically defined diseases,” said Dr. Albright. “I am excited to join the dynamic team at Editas and to help pioneer this exciting wave of innovation around genomic medicines.”
Over his career, Dr. Albright has led discovery programs that advanced investigational medicines into clinical development in a wide range of therapeutic areas, including neurodegeneration, pain, psychiatry, oncology and inflammation. Prior to his position as Vice President of Genetically Defined Diseases and Genomics, he held multiple scientific leadership roles in Neuroscience Biology at BMS. Previously, he held positions at
Forward Looking Statements
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company’s product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Quarterly Report on Form 10-Q, which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Dan Budwick Pure Communications, Inc.(973) 271-6085 email@example.com Investor Contact Jesse BaumgartnerStern Investor Relations, Inc. (212) 362-1200 firstname.lastname@example.org